Biomedical Engineering Reference
In-Depth Information
22. Millan JL. (2006) Mammalian alkaline phosphatases, from
biology to applications in medicine and biotechnology. Wiley-
VCH Verlag GmbH & Co., Weinheim, Germany.
23. Millan JL, Narisawa S, Lemire I, Loisel TP, Boileau G,
Leonard P, et al. (2008) Enzyme replacement therapy for
murine hypophosphatasia. J. Bone Miner. Res. 23, 777-787.
24. McKee MD, Nakano Y, Masica DL, Gray JJ, Lemire I, Heft R,
et al. (2011) Enzyme replacement therapy prevents dental
defects in a model of hypophosphatasia. J. Dent. Res. 90,
470-476.
25. Nishioka T, Tomatsu S, Gutierrez MA, Miyamoto K, Tranda-
firescu GG, Lopez PL, et al. (2006) Enhancement of drug
delivery to bone: characterization of human tissue-nonspecific
alkaline phosphatase tagged with an acidic oligopeptide. Mol.
Genet. Metab. 88, 244-255.
26. Kasugai S, Fujisawa R, Waki Y, Miyamoto K, Ohya K. (2000)
Selective drug delivery system to bone: small peptide (Asp)6
conjugation. J. Bone Miner. Res. 15, 936-943.
27. Yokogawa K, Miya K, Sekido T, Higashi Y, Nomura M,
Fujisawa R, et al. (2001) Selective delivery of estradiol to
bone by aspartic acid oligopeptide and its effects on ovariec-
tomized mice. Endocrinology 142, 1228-1233.
28. Yadav MC, Lemire I, Leonard P, Boileau G, Blond L,
Beliveau M, et al. (2011) Dose response of bone-targeted
enzyme replacement for murine hypophosphatasia. Bone 49,
250-256.
29. Urlaub G, Kas E, Carothers AM, Chasin LA. (1983) Deletion
of the diploid dihydrofolate reductase locus from cultured
mammalian cells. Cell 33, 405-412.
30. Rea DW, Ultee ME, Chen SX, Loisel TP. (2008) Solutions for
purification of Fc-fusion proteins BioPharm Int. March 20-25
31. Linder CH, Narisawa S, Millan JL, Magnusson P. (2009)
Glycosylation differences contribute to distinct catalytic prop-
erties among bone alkaline phosphatase isoforms. Bone 45,
987-993.
32. Drake MT, Khosla S. (2008) Bone-targeted replacement ther-
apy for hypophosphatasia. J. Bone Miner. Res. 23, 775-776.
33. Collmann H, Mornet E, Gattenlohner S, Beck C, Girschick H.
(2009) Neurosurgical aspects of childhood hypophosphatasia.
Child. Nerv. Syst. 25, 217-223.
34. Murshed M, Harmey D, Millan JL, McKee MD, Karsenty G.
(2005) Unique coexpression in osteoblasts of broadly
expressed genes accounts for the spatial restriction of ECM
mineralization to bone. Genes Dev. 19, 1093-1104.
35. Narisawa S, Harmey D, Yadav MC, O'Neill WC, Hoylaerts
MF, Millan JL. (2007) Novel inhibitors of alkaline phosphatase
suppress vascular smooth muscle cell calcification. J. Bone
Miner. Res. 22, 1700-1710.
36. Lomashvili KA, Garg P, Narisawa S, Millan JL, O'Neill WC.
(2008) Upregulation of alkaline phosphatase and pyro-
phosphate hydrolysis: potential mechanism for uremic vascu-
lar calcification. Kidney Int. 73, 1024-1030.
37. Whyte MP, Landy H, Edgar T, Weber T, Kishnani P, Wenkert
D, et al. (2009) ENB-0040, a bone-targeted human recombi-
nant tissue nonspecific alkaline phosphatase (TNSALP) fusion
protein, in the treatment of infants and adults with hypophos-
phatasia. Bone 45(Suppl 2), S57.
38. Greenberg CR, Mhanni A, Catte D, Kishnani P, Weber T,
McGinn M, (2009) Interim results of adults and infants with
hypophosphatasia treated with bone-targeted human recombi-
nant alkaline phosphatase ENB-0040. Mol. Genet. Metab. 98,
1-16, Abstract 121.
39. Whyte MP, Greenber CR, Edgar T, Van Sickle BJ, HamdamM,
Salman N, et al. (2009) Hypophosphatasia: treatment of life-
threatening disease using bone-targeted human recombinant
tissue-nonspecific alkaline phosphatase. Annual meeting of
the American Society of Human Genetics, Friday October 23,
Abstract 138.
40. Greenberg CR, Craig S, McGinn M, Simmons J, Russell W.
(2010) Life-threatening hypophosphatasia in infants and
young children: results of long-term treatment with ENB-
0040, a bone-targeted, enzyme replacement-therapy (ERT),
and an algorithm for patient management. American Society
of Human Genetics, 60th November 06, Abstract 13.
41. Whyte MP, Greenberg CR, Wenkert D, McAlister WH, Mad-
son KL, Reeves AL, (2010) Hypophosphatasia in children:
enzyme replacement therapy using bone-targeted, tissue-non-
specific alkaline phosphatase. Annual meeting of the Ameri-
can Society of Human Genetics, 60th, November 06, Abs
3070/W.
42. Whyte M, Greenberg CR, Wenkert D, McAlister WH, Madson
KL, Reeves AL, (2010) Hypophosphatasia: enzyme replace-
ment therapy for children using bone-treated, tissue-
nonspecific alkaline phosphatase. J. Bone Miner. Res. 25,
(Suppl 1) Abstract 1016.
43. Whyte MP, Greenberg CR, Wenkert D, McAlister WH,
Madson KL, Reeves AL, (2010) Hypophosphatasia (HPP):
enzyme replacement therapy (EzRT) for children using bone-
targeted, tissue nonspecific alkaline phosphatase. Ann. Endocr.
Rev. 31, (3 Suppl 1) Abstract OR11-4.
44. Greenberg CR, Landy H, Taylor J, Simmons J, Salman N,
Bober M, et al. (2011) Hypophosphatasia: one year of treat-
ment of life-threatening disease using bone-targeted human
recombinant tissue-nonspecific alkaline phosphatase. Annual
Clinical Genetics Meeting, Abstract 4.
45. Greenberg CR, Whyte MP, Wenkert D, McAlister WH, Mad-
son KL, Reeves AL, et al. (2011) Hypophosphatasia: a six-
month controlled study in affected children using bone-tar-
geted, tissue nonspecific alkaline phosphatase. Annual Clini-
cal Genetics Meeting, Abstract 259.
46. Bishop N, Greenberg C, Craig S, McGinn M, Simmons J,
Russell W, et al. (2011) Life-threatening hypophosphatasia
(HPP): results of up to two years bone-targeted enzyme
replacement therapy (ERT) in infants and young children.
Bone 48(Suppl 2), S82.
47. Deeb AA, Bruce SN, Morris AA, Cheetham TD. (2000)
Infantile hypophosphatasia: disappointing results of treatment,
Acta Paediatr. 89, 730-733.
48. Whyte MP, Mumm S, Deal C. (2007) Adult hypophosphatasia
treated with teriparatide. J.Clin. Endocrinol. Metabol. 92,
1203-1208.
Search WWH ::
Custom Search